Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Revelation Biosciences Inc WT (REVBW)

Revelation Biosciences Inc WT (REVBW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ -120 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade REVBW with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 05/27/24
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0100 +32.00%
on 04/23/24
0.0344 -61.63%
on 03/26/24
-0.0029 (-18.01%)
since 03/20/24
3-Month
0.0050 +164.00%
on 02/01/24
0.0344 -61.63%
on 03/26/24
+0.0061 (+85.92%)
since 01/23/24
52-Week
0.0050 +164.00%
on 02/01/24
0.0344 -61.63%
on 03/26/24
-0.0049 (-27.07%)
since 04/21/23

Most Recent Stories

More News
Revelation Biosciences Inc. Announces Closing of $5 Million Public Offering

SAN DIEGO, July 29, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

REVBW : 0.0132 (N/A)
REVB : 2.09 (unch)
Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering

SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

REVBW : 0.0132 (N/A)
REVB : 2.09 (unch)
Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

SAN DIEGO, July 22, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

REVBW : 0.0132 (N/A)
REVB : 2.09 (unch)
Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

-Data anticipated in Q3 2022-...

REVBW : 0.0132 (N/A)
REVB : 2.09 (unch)
Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2022 and Recent Corporate Progress

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

REVBW : 0.0132 (N/A)
REVB : 2.09 (unch)
Revelation Biosciences Inc. Announces Conference Call to Provide a Corporate Update

-CLEAR Study enrollment ongoing top-line data expected 2H 2022- -Diagnostic partnering discussions ongoing- SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE)...

REVBW : 0.0132 (N/A)
REVB : 2.09 (unch)
Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza Infection

SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

REVBW : 0.0132 (N/A)
REVB : 2.09 (unch)
Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor Conference

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

REVBW : 0.0132 (N/A)
REVB : 2.09 (unch)
Revelation Biosciences Raises $7.76 Million in Equity Financing

SAN DIEGO, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

REVBW : 0.0132 (N/A)
REVB : 2.09 (unch)
REPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company

-A greater than 50% reduction in SARS-CoV-2 Delta viral load was observed- -REVTx-99 was tested prior to infection in multiple standard in vitro...

REVB : 2.09 (unch)
REVBW : 0.0132 (N/A)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar